MARKET

CTMX

CTMX

CytomX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.85
-0.01
-0.13%
After Hours: 7.85 0 0.00% 16:10 02/26 EST
OPEN
7.86
PREV CLOSE
7.86
HIGH
7.92
LOW
7.53
VOLUME
1.41M
TURNOVER
--
52 WEEK HIGH
15.44
52 WEEK LOW
3.595
MARKET CAP
475.00M
P/E (TTM)
-11.0970
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 1d ago
CytomX Therapeutics (CTMX) Gets a Buy Rating from H.C. Wainwright
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on CytomX Therapeutics (CTMX), with a price target of $12.00. The
SmarterAnalyst · 1d ago
CytomX Therapeutics (CTMX) Receives a Buy from Mizuho Securities
SmarterAnalyst · 1d ago
DJ CytomX Therapeutics, Inc. CEO Sean McCarthy on Q4 2020 Results -- Earnings Call Transcript >CTMX
Dow Jones · 1d ago
8-K: CytomX Therapeutics, Inc.
(EDGAR Online via COMTEX) -- false 0001501989 0001501989 2021-02-24 2021-02-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 1d ago
BRIEF-CytomX Therapeutics Announces Q4 Total Revenues $16.4 Mln
reuters.com · 1d ago
CytomX Therapeutics Q4 EPS $(0.71) Misses $(0.50) Estimate, Sales $16.40M Beat $15.41M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.50) by 42 percent. This is a 10.13 percent increase over losses of $(0.79) per share
Benzinga · 2d ago
CytomX beats on revenue
CytomX (CTMX): Q4 Revenue of $16.4M beats by $0.3M.Cash, cash equivalents and short-term investments totaled $316.1M as of December 31, 2020Press Release
Seekingalpha · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTMX. Analyze the recent business situations of CytomX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTMX stock price target is 12.56 with a high estimate of 18.00 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 211
Institutional Holdings: 40.89M
% Owned: 67.58%
Shares Outstanding: 60.51M
TypeInstitutionsShares
Increased
43
4.17M
New
25
-441.49K
Decreased
50
2.28M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/President/Chief Executive Officer/Director
Sean McCarthy
Chief Financial Officer/Senior Vice President
Carlos Campoy
Senior Vice President
Leslie Robbins
Executive Vice President
Amy Peterson
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Lloyd Rowland
Senior Vice President
Marcia Belvin
Senior Vice President
Nick Galli
Vice President
Jason Braun
Senior Vice President
Alison Hannah
Lead Director/Independent Director
Matthew Young
Vice President
Glenn Michelson
Director
Mani Mohindru
Independent Director
Charles Fuchs
Independent Director
Halley Gilbert
Independent Director
Frederick Gluck
Independent Director
Elaine Jones
Independent Director
James Meyers
Independent Director
John Scarlett
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Webull offers kinds of CytomX Therapeutics Inc stock information, including NASDAQ:CTMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTMX stock methods without spending real money on the virtual paper trading platform.